Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

被引：12
|
作者：
Hifumi, Toru [1 ]
Isokawa, Shutaro [1 ]
Otani, Norio [1 ]
Ishimatsu, Shinichi [1 ]
机构：
[1] St Lukes Int Hosp, Dept Emergency & Crit Care Med, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan
来源：
CRITICAL CARE | 2020年 / 24卷 / 01期
关键词：
COVID-19; Adverse events; Nafamostat mesylate; Favipiravir;
D O I：
10.1186/s13054-020-03227-4
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
    Toru Hifumi
    Shutaro Isokawa
    Norio Otani
    Shinichi Ishimatsu
    Critical Care, 24
  • [2] Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
    Doi, Kent
    Ikeda, Mahoko
    Hayase, Naoki
    Moriya, Kyoji
    Morimura, Naoto
    CRITICAL CARE, 2020, 24 (01)
  • [3] Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
    Kent Doi
    Mahoko Ikeda
    Naoki Hayase
    Kyoji Moriya
    Naoto Morimura
    Critical Care, 24
  • [4] Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
    Abduljabbar, Maram H.
    ANNALS OF MEDICINE AND SURGERY, 2021, 68
  • [5] Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
    Hernandez-Mitre, Maria Patricia
    Tong, Steven Y. C.
    Denholm, Justin T.
    Dore, Gregory J.
    Bowen, Asha C.
    Lewin, Sharon R.
    Venkatesh, Balasubramanian
    Hills, Thomas E.
    McQuilten, Zoe
    Paterson, David L.
    Morpeth, Susan C.
    Roberts, Jason A.
    CLINICAL PHARMACOKINETICS, 2022, 61 (10) : 1331 - 1343
  • [6] Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
    María Patricia Hernández-Mitre
    Steven Y. C. Tong
    Justin T. Denholm
    Gregory J. Dore
    Asha C. Bowen
    Sharon R. Lewin
    Balasubramanian Venkatesh
    Thomas E. Hills
    Zoe McQuilten
    David L. Paterson
    Susan C. Morpeth
    Jason A. Roberts
    Clinical Pharmacokinetics, 2022, 61 : 1331 - 1343
  • [7] Evaluation of potential cardiovascular adverse events of Remdesivir and Favipiravir in COVID-19 patients
    Dewi, Kristin Purnama
    Dewi, Ivana Purnama
    Iswanto, Iswanto
    Budiarti, Endang
    Kusmiati, Tutik
    RESPIROLOGY, 2023, 28 : 36 - 36
  • [8] Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
    Ergur, Figen Ozturk
    Yildiz, Murat
    Sener, Melahat Uzel
    Kavurgaci, Suna
    Ozturk, Ayperi
    SAO PAULO MEDICAL JOURNAL, 2022, 140 (03): : 372 - 377
  • [9] The safety and adverse event profile of favipiravir in the treatment of COVID-19 patients, Turkey
    Tigen, Elif Tukenmez
    Sengel, Buket Erturk
    Ozben, Beste
    Gurun, Hande Perk
    Balcan, Baran
    Bilgili, Beliz
    Gul, Fethi
    Odabasi, Zekaver
    Korten, Volkan
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2023, 17 (11): : 1549 - 1555
  • [10] Incidence and risk factors for hyperkalaemia in patients treated for COVID-19 with nafamostat mesylate
    Kodama, Kentaro
    Imai, Toru
    Asai, Yasuo
    Kozu, Yutaka
    Hayashi, Kentaro
    Shimizu, Tetsuo
    Gon, Yasuhiro
    Ootsuka, Susumu
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (07) : 1070 - 1078
12345